In Stock Cell Lines
Homo sapiens (Human)
Skin
Adherent
CRISPR/Cas9-edited JPX knockout in the A-375 human melanoma cell line. This model disrupts the JPX lncRNA, which recruits CTCF and PRC2 to activate XIST transcription and propagate X-chromosome inactivation through H3K27me3 deposition. It provides a clean background to study how pluripotency factors (OCT4, SOX2, NANOG) intersect with epigenetic silencing. Ideal for investigating X-inactivation mechanisms, lncRNA biology, and epigenetic dysregulation in melanoma. Validated for RNA FISH, RIP, ChIP-qPCR, RT-qPCR, and proliferation assays. Enables elucidation of JPX??s role in cancer cell fitness and chromatin modification.
ASZ1 Knockout HAP1 Polyclonal Cells
Cat. No. ARG21963
MYLK Knockout NCI-H1975 Polyclonal Cells
Cat. No. ARG17315
HSD3B1 Knockout HAP1 Polyclonal Cells
Cat. No. ARG34575
DYRK4 Knockout HEK293T Polyclonal Cells
Cat. No. ARG40209
OVKATE
Cat. No. ARC1037
Rat Abdominal Aortic Smooth Muscle Cells
Cat. No. ARP0200
The JPX Knockout A-375 Cell Line is a CRISPR/Cas9-edited knockout cell line that disrupts the JPX long non-coding RNA (lncRNA) gene, a critical activator of XIST transcription and X-chromosome inactivation. This loss-of-function model enables dissection of JPX-dependent epigenetic silencing without introducing exogenous sequences. Generated via CRISPR/Cas9-mediated gene disruption, the line provides a genetically defined background to study lncRNA-mediated regulation of chromatin and gene expression. It is supplied as a proliferating cell line, ready for experiments examining the functional consequences of JPX ablation on XIST expression, PRC2 recruitment, and H3K27me3 deposition.
The A-375 host cell line originates from a primary cutaneous malignant melanoma of a 54-year-old female. These adherent cells retain hallmark features of aggressive melanoma, including rapid growth and metastatic gene signatures. A-375 is a well-established model for investigating oncogenic signaling, epigenetic dysregulation, and therapeutic responses in melanoma. Its human origin and tumorigenic background make it ideal for exploring how lncRNAs like JPX modulate cancer-relevant epigenetic programs and cellular phenotypes.
JPX acts mechanistically by binding the insulator protein CTCF and recruiting polycomb repressive complex 2 (PRC2) to the XIST promoter. This interaction catalyzes trimethylation of histone H3 at lysine 27 (H3K27me3), initiating XIST transcription and spreading of X-chromosome inactivation. Upstream, pluripotency transcription factors OCT4, SOX2, and NANOG regulate JPX expression, linking developmental cues to epigenetic silencing. The JPX?CCTCF?CPRC2?CXIST axis thus orchestrates large-scale chromatin remodeling, with JPX serving as a scaffold for silencing complex assembly.
In melanoma, aberrant lncRNA expression can rewire epigenetic landscapes to promote proliferation and survival. Because JPX lies upstream of XIST, its knockout in A-375 cells permits direct assessment of XIST-dependent and -independent roles in malignant phenotypes. Loss of JPX may alter H3K27me3 distribution beyond the X chromosome, affecting gene networks relevant to melanoma progression. This model can reveal whether JPX contributes to tumor cell fitness through canonical X-inactivation pathways or through alternative mechanisms involving PRC2 recruitment to autosomal targets.
This cell line is suited to a broad array of experimental approaches. RNA fluorescence in situ hybridization (RNA FISH) visualizes XIST localization; RNA immunoprecipitation (RIP) profiles JPX?CCTCF or JPX?CPRC2 interactions; chromatin immunoprecipitation quantitative PCR (ChIP-qPCR) measures H3K27me3 occupancy at the XIST locus; RT-qPCR quantifies XIST transcript levels; and proliferation assays evaluate functional effects. Together, these tools enable rigorous investigation of lncRNA-driven epigenetic regulation in cancer. For further technical information, please contact Ascent Research.
